Freedom Investment Management’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-7,468
Closed -$309K 573
2020
Q1
$309K Buy
7,468
+1,944
+35% +$78.6K 0.03% 484
2019
Q4
$286K Sell
5,524
-1,266
-19% -$73.5K 0.03% 498
2019
Q3
$373K Sell
6,790
-3,431
-34% -$176K 0.03% 438
2019
Q2
$415K Buy
+10,221
New +$373K 0.03% 409
2018
Q2
Sell
-36,393
Closed -$1.81M 954
2018
Q1
$1.81M Buy
36,393
+89
+0.2% +$5.03K 0.09% 199
2017
Q4
$1.96M Sell
36,304
-5,052
-12% -$280K 0.1% 160
2017
Q3
$2.4M Buy
41,356
+4,897
+13% +$256K 0.13% 113
2017
Q2
$1.8M Buy
36,459
+229
+0.6% +$10.5K 0.1% 146
2017
Q1
$1.57M Sell
36,230
-4,668
-11% -$223K 0.09% 173
2016
Q4
$2M Sell
40,898
-10,159
-20% -$470K 0.13% 100
2016
Q3
$2.44M Sell
51,057
-1,060
-2% -$52.4K 0.16% 74
2016
Q2
$2.8M Buy
52,117
+2,292
+5% +$108K 0.19% 50
2016
Q1
$2.23M Sell
49,825
-5,910
-11% -$240K 0.16% 74
2015
Q4
$2.13M Buy
55,735
+48,349
+655% +$1.85M 0.16% 75
2015
Q3
$229K Sell
7,386
-20,289
-73% -$707K 0.02% 571
2015
Q2
$914K Buy
+27,675
New +$987K 0.09% 174

Other funds holding ANIK

Freedom Investment Management's ANIK Position: Q2 2020 in Review

Freedom Investment Management sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 7,468 shares — an estimated $309K sold.

Freedom Investment Management first reported a position in ANIK in Q2 2015 and held it in 16 quarters. The position peaked at $2.8M in Q2 2016. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

  • Freedom Investment Management reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Freedom Investment Management sold 7,468 Anika Therapeutics shares in Q2 2020, an estimated $309K.
  • Freedom Investment Management first reported a position in Anika Therapeutics in Q2 2015 and held it in 16 quarters.
  • Freedom Investment Management's Anika Therapeutics position peaked at $2.8M in Q2 2016.
  • 158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Freedom Investment Management's 13F filing for Q2 2020, filed 10 Aug 2020.